Relative risks of death or death and non-fatal cardiovascular events combined for metoprolol compared to verapamil treatment. The figures refer both to the results at the end of the study (odds ratios) and analyses based on the Cox regression model, which takes time course into account (risk ratios). In the Cox regression model adjustments were made for imbalances concerning sex and smoking (see Table 1 ) between the groups The above-mentioned changes do not alter any statistical significances in the results or change our interpretation of the study. Neither the previous nor the present data indicate any clinically important difference between the two treatments, and we interpret our treatment results as suggesting similarity between metoprolol and verapamil. The post hoc calculations of power to detect a 30% risk reduction with one of the treatments is now 0-85 (previously 0-80) for the primary study variable, death and non-fatal cardiovascular events combined. The power was 0-21 for death alone, but the study was not designed to evaluate fatal events -this would have required a much larger study.
Due to an unfortunate error in the data base which concerned the actual dates of fatal events among patients who had previously suffered a non-fatal event (these patients were registered as if they had died at the end of the study instead of at the actual dates) we must make the following corrections in our article concerning the main results of the APSIS study.
The correct number of patient years in the study (all analyses made on an intention-to-treat basis) is 2766 and not 2887. The end of study results (odds ratios) are unchanged, but the Cox regression analyses are affected by these corrections. In Table 3 we reported separate Cox adjustments for sex and smoking, but they should have been combined, as stated in the text. This has also been corrected. Somewhat unexpectedly, ex-smokers were the group with the lowest risk in our study, which explains the effect of the imbalances reported in Table 1 on our adjusted Cox regression analyses. Accordingly, Table 3 and its legend should read as follows: Table 3 Relative risks of death or death and non-fatal cardiovascular events combined for metoprolol compared to verapamil treatment. The figures refer both to the results at the end of the study (odds ratios) and analyses based on the Cox regression model, which takes time course into account (risk ratios). In the Cox regression model adjustments were made for imbalances concerning sex and smoking (see Table 1 The above-mentioned changes do not alter any statistical significances in the results or change our interpretation of the study. Neither the previous nor the present data indicate any clinically important difference between the two treatments, and we interpret our treatment results as suggesting similarity between metoprolol and verapamil. The post hoc calculations of power to detect a 30% risk reduction with one of the treatments is now 0-85 (previously 0-80) for the primary study variable, death and non-fatal cardiovascular events combined. The power was 0-21 for death alone, but the study was not designed to evaluate fatal events -this would have required a much larger study.
Statement from Professors Lars Ryden and Klas Malmberg in connection with the Angina Prognosis Study in Stockholm (APSIS)
The above Erratum indicates that the number of patient years is slightly lower than that originally stated and affects the Cox regression analysis. As soon as the error was detected we were contacted by the authors who were aware of our editorial regarding APSIS and TIBET. We were fully informed about the reasons behind the error and were given the opportunity to scrutinize Table 3 . After having reviewed the new data, our opinion about the study and its conclusions is unchanged.
